Drugs / Voglibose
Voglibose
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01263509 | Jun 2007 → Oct 2008 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05688332 | Aug → Dec 2023 | type 2 diabetes mellitus | University of Zambia | Unknown | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02049814 | May 2014 → Jun 2016 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT01309698 | Feb → Apr 2011 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02287402 | Mar 2010 → Nov 2012 | glucose intolerance | Takeda | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00724542 | Jul 2008 → Dec 2010 | coronary artery disorder, glucose intolerance | Ministry of Science and Technology of the People´s Republic of China | Unknown | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 2 | NCT01263496 Comparator | May 2007 → Sep 2008 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT01263470 Comparator | Jan → Dec 2007 | type 2 diabetes mellitus | Takeda | Completed | Met primary |
| Phase 2/3 | NCT01263483 Background | Jan 2007 → Apr 2008 | type 2 diabetes mellitus | Takeda | Completed | Met primary |
| Phase 3 | NCT01242202 Background | Oct 2010 → May 2012 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00837577 Background | Feb 2009 → Aug 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00654381 Comparator | Apr 2008 → Jan 2010 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT00411554 Comparator | Jan → Aug 2007 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 4 | NCT02097342 Comparator | Dec 2013 → Nov 2014 | type 2 diabetes mellitus | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT00970528 Comparator | Nov 2009 → Mar 2012 | type 2 diabetes mellitus | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00663884 Comparator | Feb 2008 → Jul 2009 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | Met primary |
| — | NCT00212017 Comparator | Apr 2005 → Jun 2012 | glucose intolerance, myocardial infarction | National Cerebral and Cardiovascular Center, Japan | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | voglibose | “Voglibose” NCT01242202 ↗ |
| Known as | A-71100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL476960 ↗ |
| Known as | AO-128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02287402 ↗ |
| Known as | Basen | “Voglibose (Basen)” NCT00970528 ↗ |
| Known as | Voglibosa | ChEMBL registry synonym — accepted as the source's own label CHEMBL476960 ↗ |
| Action | Inhibit | “We evaluated the effects of an alpha-glucosidase inhibitor, voglibose, on cardiovascular events in patients with a previous myocardial infarction (MI) and impaired glucose...” PMID 28779371 ↗ Aug 2017 |
| Modality | Small molecule | — CHEMBL476960 ↗ |
| Route | Oral | “voglibose 0.2 mg orally three times daily TID” NCT00411554 ↗ |